• Publications
  • Influence
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.
Lymphomas arising from NK or γδ-T cells are very aggressive diseases and little is known regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and STAT5B in NK/T-cellExpand
  • 221
  • 16
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma
Follicular lymphoma (FL) is typically an indolent disease, but 30–40% of FL cases transform into an aggressive lymphoma (tFL) with a poor prognosis. To identify the genetic changes that drive thisExpand
  • 49
  • 2
Targeting of B‐cell receptor signalling in B‐cell malignancies
Pharmacological agents that inhibit enzymes of the B‐cell receptor (BCR) pathway are of increasing importance in the treatment of B‐cell malignancies. These include inhibitors of Bruton tyrosineExpand
  • 32
  • 1
  • PDF
Activating mutations of STAT 5 B and STAT 3 in lymphomas derived from gdT or NK cells
Can Küçük1,*, Bei Jiang1,*, Xiaozhou Hu1, Wenyan Zhang2, John K.C. Chan3, Wenming Xiao4, Nathan Lack5, Can Alkan6, John C. Williams7, Kendra N. Avery7, Pınar Kavak8, Anna Scuto1, Emel Sen5, PhilippeExpand
  • 9
  • 1
  • PDF
Uniform Genomic Data Analysis in the NCI Genomic Data Commons
TLDR
The goal of the National Cancer Institute Genomic Data Commons (GDC) is to provide the cancer research community with a data repository of uniformly processed genomic and associated clinical data that enables data sharing and collaborative analysis in the support of precision medicine. Expand
  • 4
  • 1
The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study.
BACKGROUND Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot studyExpand
  • 3
Abstract 612: The NCI exceptional responders initiatives: Initial feasibility result
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Introduction: Preliminary data show that up to 10% of patients on early clinical trials have complete (CR) or partialExpand